Navigation Links
Vion Reports 2007 Fourth Quarter and Year-End Results
Date:3/17/2008

mpany implemented a one-for-ten reverse split of all outstanding shares of its common stock and a corresponding decrease in the number of shares of authorized common stock. Share and per share amounts contained herein are provided on a post-split basis.

Vion Pharmaceuticals, Inc. is committed to extending the lives and improving the quality of life of cancer patients worldwide by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute myelogenous leukemia. Clinical trials of Cloretazine(R) (VNP40101M) with temozolomide in brain tumors, and with stem cell transplantation in advanced hematologic malignancies, are also being conducted. Triapine(R), a potent inhibitor of a key step in DNA synthesis, is being evaluated in clinical trials sponsored by the National Cancer Institute. For additional information on Vion and its product development programs, visit the Company's Internet web site at http://www.vionpharm.com.

This news release contains forward-looking statements. Such statements are subject to certain risk factors which may cause Vion's plans to differ or results to vary from those expected, including Vion's potential inability to obtain regulatory approval for its products, particularly Cloretazine(R) (VNP40101M), delayed or unfavorable results of drug trials, the possibility that favorable results of earlier preclinical studies or clinical trials are not predictive of safety and efficacy results in later clinical trials, the need for additional research and testing, the potential inability to secure external sources of funding to continue operations, the inability to access capital and funding on favorable terms, continued operating losses and the inability to c
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. AutoImmune Inc. Reports 2007 Fourth Quarter and Year End Financial Results
2. Renovis Reports Fourth Quarter and Full Year 2007 Financial Results
3. Warner Chilcott Reports the Death of Its Director James Andress
4. Nile Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results
5. Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results
6. Unigene Restates Policy on Analyst Reports
7. NPS Pharmaceuticals Reports 2007 Financial Results
8. Trubion Pharmaceuticals Inc. Reports Fourth-Quarter and Year-Ended 2007 Financial Results and Provides 2008 Financial Outlook
9. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
10. Dendreon Reports Fourth Quarter and 2007 Year End Financial Results
11. MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... , March 30, 2015  Multiple new research abstracts ... several important health factors. From their impact on colon ... positive effect on both gut health and vascular health, ... detail our latest understanding of walnuts, inner workings. Running ... , this annual meeting attracts an international audience ...
(Date:3/30/2015)... US-Australian drug discovery company, Novogen Ltd, (ASX:NRT; ... and Yale University, on March 27 released pre-clinical data ... as an oral presentation by Professor Gil Mor ... 62 nd Annual Scientific Meeting of the Society ... In both in vitro and ...
(Date:3/30/2015)... 30, 2015  Spherix Incorporated (Nasdaq: SPEX ... fostering and monetization of intellectual property, today provided ... 3:13-cv-03494-M and  Spherix v. Uniden , Case No. ... for the Northern District of Texas ... v. Verizon, Case No. 1:14-cv-00721-GBL-TCB, in the ...
(Date:3/30/2015)... 2015 Richmond Pharmacology nimmt ... Pharmacology ist das erste Zentrum weltweit, das in ... Hospital in London in ... Studienversuche an einem Patienten begonnen hat. Das Therapeutikum ... entwickelt (ATTR), einer seltenen Herz- und Nervenkrankheit. ...
Breaking Biology Technology:New Findings Support the Benefits of Eating Walnuts on Overall Health 2New Findings Support the Benefits of Eating Walnuts on Overall Health 3New Findings Support the Benefits of Eating Walnuts on Overall Health 4Yale University and Novogen Release Data on Cantrixil Mode of Action 2Yale University and Novogen Release Data on Cantrixil Mode of Action 3Yale University and Novogen Release Data on Cantrixil Mode of Action 4Spherix Provides Update on Litigation vs. VTech, Uniden and Verizon 2Spherix Provides Update on Litigation vs. VTech, Uniden and Verizon 3
... N.J., March 18 Sopherion Therapeutics, LLC, a ... of anti-cancer therapies, announced that it completed enrollment ... liposomal doxorubicin (Myocet(TM)) in metastatic HER-2-overexpressing breast cancer. ... of Sopherion,s lead product in combination with the ...
... Troy, N.Y. Researchers at Rensselaer Polytechnic Institute ... copper nanorods, a key step for advancing integrated ... fuse together, or anneal, at about 300 degrees ... the nanorods ideal for use in heat-sensitive nanoelectronics, ...
... PLYMOUTH MEETING, Pa., March 17 /PRNewswire-Asia-FirstCall/ -- BMP,Sunstone Corporation (Nasdaq: ... for the fourth quarter and fiscal year ended,December 31, 2008. , ... -- Fourth quarter revenues increased to $36.6 million, ... fourth quarter of 2007., -- Non-GAAP operating income, ...
Cached Biology Technology:Sopherion Therapeutics Announces Completion of Enrollment in Phase III Study of Myocet in Metastatic Breast Cancer 2Sopherion Therapeutics Announces Completion of Enrollment in Phase III Study of Myocet in Metastatic Breast Cancer 3Slimmer, stickier nanorods give boost to 3-D computer chips 2BMP Sunstone Reports Fourth Quarter and Full Year 2008 Financial Results 2BMP Sunstone Reports Fourth Quarter and Full Year 2008 Financial Results 3BMP Sunstone Reports Fourth Quarter and Full Year 2008 Financial Results 4BMP Sunstone Reports Fourth Quarter and Full Year 2008 Financial Results 5BMP Sunstone Reports Fourth Quarter and Full Year 2008 Financial Results 6BMP Sunstone Reports Fourth Quarter and Full Year 2008 Financial Results 7BMP Sunstone Reports Fourth Quarter and Full Year 2008 Financial Results 8BMP Sunstone Reports Fourth Quarter and Full Year 2008 Financial Results 9BMP Sunstone Reports Fourth Quarter and Full Year 2008 Financial Results 10BMP Sunstone Reports Fourth Quarter and Full Year 2008 Financial Results 11BMP Sunstone Reports Fourth Quarter and Full Year 2008 Financial Results 12
(Date:3/20/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/4stcg3/india_sensors ) ... Sensors Market Forecast and Opportunities 2020" report ... is projected to grow at a CAGR over ... industrial and healthcare sectors are the key application ... adoption of MEMS technology in sensors is growing ...
(Date:3/20/2015)... 19, 2015 Research and Markets ( http://www.researchandmarkets.com/research/vkzvcs/iris_biometrics ... - Global Strategic Business Report" report to their offering. ... Biometrics in US$ Thousands. The report provides separate comprehensive analytics ... Japan , Europe , ... Latin America . Annual estimates ...
(Date:3/17/2015)... , March 17, 2015 MedNet ... specializing in clinical study management systems, is pleased ... attendance at ARENA,s Outsourcing in Clinical Trials Southeast ... event provides an excellent forum for MedNet to ... and affordable software-as-a-service (SaaS) eClinical technology platform. ...
Breaking Biology News(10 mins):India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2
... who contract gastroenteritis from drinking water contaminated with ... high blood pressure, kidney problems and heart disease in later ... Medical Journal . The findings underline the importance of ... for regular monitoring for those affected. It is estimated ...
... Physical activity promotes changes in the brain that ... of Alzheimer,s disease, according to a new study done ... Carson Smith, an assistant professor of health sciences, included ... gene for Alzheimer,s disease, and other healthy older adults ...
... Va. Since the Civil War, the stethoscope has been ... average doctor may be toting another valuable diagnostic tool: a ... professor of internal medicine at Eastern Virginia Medical School, believes ... years they will become commonplace," he predicts. Dr. Levitov, ...
Cached Biology News:E coli infection linked to long-term health problems 2Study shows importance of exercise for those at special risk for Alzheimer's 2Author predicts widespread acceptance of pocket-sized ultrasound machines 2
Human FADD Affinity Purified Polyclonal Ab...
Immunogen: Synthetic peptide based on the sequence: SPSSGPSLTADSMWR Storage: -20 C, Avoid Freeze/Thaw Cycles...
Mouse Endoglin/CD105 Fluorescein MAb (Clone 209701)...
... Ac-DEVD-CHO is an ... activity. The concentration of ... caspase activity must be ... system. Ten micromolar inhibitor ...
Biology Products: